RC
ADMA icon

RegentAtlantic Capital’s ADMA Biologics ADMA Stock Holding History

RegentAtlantic Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-500
Closed -$5.58K – 372
2014
Q4 		$5.58K Buy
+500
New +$5.72K ﹤0.01% 996

Other funds holding ADMA

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

RegentAtlantic Capital's ADMA Position: Q1 2015 in Review

RegentAtlantic Capital sold out of ADMA Biologics (ADMA) in Q1 2015, closing a stake of 500 shares — an estimated $5.58K sold.

RegentAtlantic Capital first reported a position in ADMA in Q4 2014 and held it in 1 quarter. The position peaked at $5.58K in Q4 2014. 19 funds tracked by Wall St. Rank hold ADMA as of Q1 2015.

  • RegentAtlantic Capital reported no remaining ADMA Biologics position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 500 ADMA Biologics shares in Q1 2015, an estimated $5.58K.
  • RegentAtlantic Capital first reported a position in ADMA Biologics in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's ADMA Biologics position peaked at $5.58K in Q4 2014.
  • 19 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.